- VYGR Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
S-3 Filing
Voyager Therapeutics (VYGR) S-3Shelf registration
Filed: 1 Dec 16, 12:00am
Exhibit 12.1
Computation of Ratio of Earnings to Fixed Charges
|
| Period Ended |
| Year Ended December 31, |
| Nine Months Ended |
| |||||||||
|
| 2013 |
| 2014 |
| 2015 |
| 2016 |
| |||||||
Net loss attributable to common stockholders (1) |
| $ | (3,833 | ) | $ | (17,683 | ) | $ | (38,290 | ) | $ | (25,520 | ) | |||
Fixed charges |
|
|
|
|
|
|
|
|
| |||||||
Interest expense |
|
|
|
|
|
|
|
|
| |||||||
Total fixed charges |
|
|
|
|
|
|
|
|
| |||||||
Net loss attributable to common stockholders plus fixed charges |
| $ | (3,833 | ) | $ | (17,683 | ) | $ | (38,290 | ) | $ | (25,520 | ) | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
Ratio of earnings to fixed charges (2) |
| N/A |
| N/A |
| N/A |
| N/A |
| |||||||
(1) The deficiency of earning available to cover combined fixed charges and preferred dividends includes non-cash deemed dividends to preferred stockholders and accretion of redemption value of redeemable convertible preferred stock of $1,366 and $8,618 for the years ended December 31, 2014 and 2015, respectively.
(2) Due to the Company’s net loss for the period ended December 31, 2013 and for each of the years ended December 31, 2014 and 2015 and for the nine months ended September 30, 2016, earnings were insufficient to cover combined fixed charges.